|
Mar 1
|
Sage Therapeutics, Inc. (SAGE): Among the Best Psychedelic Stocks to Buy in 2025
|
|
Feb 25
|
Is Sage Therapeutics, Inc. (SAGE) the Best Small-Cap Growth Stock to Buy Now?
|
|
Feb 13
|
Sage Therapeutics price target lowered to $12 from $14 at Scotiabank
|
|
Feb 12
|
Sage Therapeutics' Q4 Earnings Miss Mark, Revenues Plunge Y/Y
|
|
Feb 12
|
Q4 2024 SAGE Therapeutics Inc Earnings Call
|
|
Feb 12
|
Sage Therapeutics Inc (SAGE) Q4 2024 Earnings Call Highlights: Strong Prescription Growth Amid ...
|
|
Feb 11
|
Sage Therapeutics, Inc. (SAGE) Reports Q4 Loss, Lags Revenue Estimates
|
|
Feb 11
|
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
|
|
Jan 30
|
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
|
|
Jan 29
|
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
|
|
Jan 28
|
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
|
|
Jan 28
|
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
|
|
Jan 28
|
Sage rejects Biogen’s $469m takeover bid
|
|
Jan 27
|
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
|
|
Jan 27
|
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
|